trending Market Intelligence /marketintelligence/en/news-insights/trending/rQb3DbFOlARCnDTrCpmqZA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

UK's NICE rejects Clovis Oncology's Rubraca for certain relapsed cancers

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

UK's NICE rejects Clovis Oncology's Rubraca for certain relapsed cancers

The U.K.'s National Institute for Health and Care Excellence did not recommend Clovis Oncology Inc.'s Rubraca to treat patients with certain kinds of cancer that have returned, citing cost concerns.

NICE evaluated Rubraca, or rucaparib, as a single therapy for epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer in patients who have relapsed after taking chemotherapy.

The drug pricing watchdog stated in an Aug. 6 draft guidance that the drug costs £3,562 for a pack of 60 pills and that the average cost of treatment is £110,897.

The cancers that Rubraca is meant to treat come with a high disease burden and resistance to platinum-based chemotherapy, leading to relapse, is also high, NICE noted in the draft guidance.

But using the organization's incremental cost-effectiveness ratio, which evaluates the years of life and quality of life that a drug provides compared to its price, at £36,387 per year gained, Rubraca was above the range that NICE uses as a threshold which is £20,000 to £30,000.

Rubraca was also ineligible to be included in the U.K.'s Cancer Drugs Fund due to insufficient data.

NICE will accept comments on the draft until Aug. 27 before a second appraisal meeting Sept. 11.